BQ-A Clinical Plans
While the therapeutic targets for BQ-A are broad in scope, Bioquark is focusing to generating human clinical data in discreet disease indications that represent areas of substantial unmet medical need.
Despite spending close to a trillion dollars in the “war on cancer” to date, the disease remains one of our major killers.
Problems with existing therapeutic strategies such as fractional cell killing and rapid resistance development continue to plague even the most modern “smart drugs” rendering them ineffective in the long run. Many of the new targets discovered during the genomics revolution are considered un-druggable by big pharma.
With recent understandings that cancer is no longer a static disease of homogeneous cell populations, as once thought, but much more of a dynamic disease with heterogeneous cell populations constantly altering their regulatory state, entirely new therapeutic approaches are called for.
Bioquark is focusing on using its biologic candidates to alter the entire regulatory state of cancer lesions in-vivo, leading to reprogramming, remodeling and normalization of diseased tissues.
The first organ that the company is focusing on, based on a combination of unmet medical need and minimal competitive landscape, is the human kidney.
While humans can live normally with just one kidney, when the amount of functioning kidney tissue is greatly diminished by disease or damage, chronic kidney disease will develop leading towards a progressive loss in function. This loss of kidney function leads to a downward spiral throughout the body including negative effects on the cardiovascular system, nervous systems, and endocrine function.
Dialysis or kidney transplant can prolong life, but quality of life is severely affected, supplies are limited, and costs of long term maintenance are exorbitant. Additionally, as the kidney is one of the more anatomically complex organs, it has proven refractory to stem cell-based regenerative techniques to date.
According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in 2007, over 500,000 Americans suffered from End-Stage Renal Disease (ESRD), with over 111,000 new cases diagnosed and 90,000 deaths annually.
Over $30 billion in care was spent on these patients, with 370,000 on dialysis ($70,000/year/patient), and 17,000 kidney transplants ($116,000 year 1; immunosuppression – $20,000/year/patient).
Disorders of Consciousness / Brain Death
Brain death is the legal definition of human death in most countries around the world.
However, while humans lack substantial regenerative capabilities in the CNS, many non-human species can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.
We are at a very unique moment in history where the convergence of the tools of regenerative biology, resuscitation / reanimation research, and clinical neuroscience have placed us on the verge of major scientific breakthroughs.
To receive further confidential information about Bioquark’s plans in this space, please place the phrase “BQ-Phoenix” in the subject line of our contact form, or visit the Reanima Project site at http://www.reanima.tech
Additionally, please visit our partner company RegenerAge SAPI de CV (www.regenerage.clinic/en) to learn more about on-going compassionate care opportunities.